Absci Corporation Company Profile
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Absci at a glance
Absci Corporation (NASDAQ: ABSI) is a Biotechnology: Commercial Physical & Biological Resarch company in the Health Care sector headquartered in Vancouver, WA. Absci is led by Mr. Sean McClain and employs about 140 people. The company's shares have traded publicly since 2021.
At a market capitalization of $1.53 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001672688, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Absci do?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Business description based on the company's public filings.
Company information
- Legal name
- Absci Corporation
- Ticker
- NASDAQ: ABSI
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Sean McClain
- Employees
- 140
- Headquarters
- 18105 SE Mill Plain Boulevard, Vancouver, WA, United States
- Phone
- 360 949 1041
- Website
- absci.com
- IPO year
- 2021
- Market cap
- $1.53B
- SEC CIK
- 0001672688
Companies similar to Absci
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRCNRC Health | 20.42 | +1.14% | $451.68M | vs ABSI |
| CRLCharles River Laboratories International Inc. | 298.00 | -0.77% | $14.35B | vs ABSI |
| MEDPMedpace Holdings Inc. | 602.70 | -0.26% | $16.82B | vs ABSI |
| IQVIQVIA Holdings Inc. | 258.88 | +0.30% | $42.61B | vs ABSI |